Adaptive monitoring using the endangered northern corroboree frog (Pseudophryne pengilleyi) as a case study

Abstract Monitoring programs are most successful when they undertake regular evaluation of their data to determine if the goals of the programs are achievable and allow changes to achieve this as necessary -so called adaptive monitoring. We use data from a monitoring program for the northern corroboree frog (Pseudophryne pengilleyi), a declining species in south-eastern Australia, to determine the inter-annual variability in the counts and assess what levels of population change would be detectable using different statistical and monitoring approaches. The existing monitoring program would only successfully statistically detect a 3% annual decline (34% total decline) in population size over a ten year period. Monitoring 40 sites would allow an 80% or greater chance of detecting a 2% or greater annual increase over a ten year period (22% increase). Detecting population decreases is more difficult as monitoring 40 sites with a 2% annual decline (19% total decline) will have a less than 40% chance of being detected after 10 years. A larger monitoring program is required to detect smaller annual changes in the population of this species. These findings have implications for the likely effectiveness of other anuran monitoring programs as the northern corroboree frog appears to be far more consistent in detectable call effort compared to most species

TOI-4010: A System of Three Large Short-Period Planets With a Massive Long-Period Companion

We report the confirmation of three exoplanets transiting TOI-4010 (TIC-352682207), a metal-rich K dwarf observed by TESS in Sectors 24, 25, 52, and 58. We confirm these planets with HARPS-N radial velocity observations and measure their masses with 8 - 12% precision. TOI-4010 b is a sub-Neptune ($P = 1.3$ days, $R_{p} = 3.02_{-0.08}^{+0.08}~R_{\oplus}$, $M_{p} = 11.00_{-1.27}^{+1.29}~M_{\oplus}$) in the hot Neptune desert, and is one of the few such planets with known companions. Meanwhile, TOI-4010 c ($P = 5.4$ days, $R_{p} = 5.93_{-0.12}^{+0.11}~R_{\oplus}$, $M_{p} = 20.31_{-2.11}^{+2.13}~M_{\oplus}$) and TOI-4010 d ($P = 14.7$ days, $R_{p} = 6.18_{-0.14}^{+0.15}~R_{\oplus}$, $M_{p} = 38.15_{-3.22}^{+3.27}~M_{\oplus}$) are similarly-sized sub-Saturns on short-period orbits. Radial velocity observations also reveal a super-Jupiter-mass companion called TOI-4010 e in a long-period, eccentric orbit ($P \sim 762$ days and $e \sim 0.26$ based on available observations). TOI-4010 is one of the few systems with multiple short-period sub-Saturns to be discovered so far.Comment: 26 pages, 16 figures, published in A

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. Targeted monotherapies produce high regression rates, albeit for limited patient subgroups, who inevitably succumb. We present a novel strategy for identifying customized combinations of triplets of targeted agents, utilizing a simplified interventional mapping system (SIMS) that merges knowledge about existent drugs and their impact on the hallmarks of cancer. Based on interrogation of matched lung tumor and normal tissue using targeted genomic sequencing, copy number variation, transcriptomics, and miRNA expression, the activation status of 24 interventional nodes was elucidated. An algorithm was developed to create a scoring system that enables ranking of the activated interventional nodes for each patient. Based on the trends of co-activation at interventional points, combinations of drug triplets were defined in order to overcome resistance. This methodology will inform a prospective trial to be conducted by the WIN consortium, aiming to significantly impact survival in metastatic NSCLC and other malignancies

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. Targeted monotherapies produce high regression rates, albeit for limited patient subgroups, who inevitably succumb. We present a novel strategy for identifying customized combinations of triplets of targeted agents, utilizing a simplified interventional mapping system (SIMS) that merges knowledge about existent drugs and their impact on the hallmarks of cancer. Based on interrogation of matched lung tumor and normal tissue using targeted genomic sequencing, copy number variation, transcriptomics, and miRNA expression, the activation status of 24 interventional nodes was elucidated. An algorithm was developed to create a scoring system that enables ranking of the activated interventional nodes for each patient. Based on the trends of co-activation at interventional points, combinations of drug triplets were defined in order to overcome resistance. This methodology will inform a prospective trial to be conducted by the WIN consortium, aiming to significantly impact survival in metastatic NSCLC and other malignancies